KRAS and extended RAS molecular profiling in metastatic colorectal cancer

References

• Saltz LB , ClarkeS, Díaz-RubioEet al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study. J. Clin. Oncol.26(12), 2013–2019 (2008).
   PubMed Web of Science ®Google Scholar
• Hurwitz H , FehrenbacherL, NovotnyWet al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350(23), 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Douillard J-Y , SienaS, CassidyJet al. Randomized, Phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol.28(31), 4697–4705 (2010).
   PubMed Web of Science ®Google Scholar
• Mendelsohn J . Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol.20(Suppl. 1), S1–S13 (2002).
   PubMedGoogle Scholar
• Cunningham D , HumbletY, SienaSet al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med.351(4), 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Jonker DJ , O'CallaghanCJ, KarapetisCSet al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med.357(20), 2040–2048 (2007).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E , PeetersM, SienaSet al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol.25(13), 1658–1664 (2007).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E , KöhneC-H, HitreEet al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med.360(14), 1408–1417 (2009).
   PubMed Web of Science ®Google Scholar
• Chung KY , ShiaJ, KemenyNEet al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol.23(9), 1803–1810 (2005).
   PubMed Web of Science ®Google Scholar
• Amado RG , WolfM, PeetersMet al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol.26(10), 1626–1634 (2008).
   PubMed Web of Science ®Google Scholar
• Karapetis CS , Khambata-FordS, JonkerDJet al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med.359(17), 1757–1765 (2008).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C , BondarenkoI, HartmannJTet al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann. Oncol.22(7), 1535–1546 (2011).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E , KöhneC-H, LángIet al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol.29(15), 2011–2019 (2011).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C , BondarenkoI, MakhsonAet al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol.27(5), 663–671 (2009).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C , Van CutsemE, RougierPet al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur. J. Cancer48(10), 1466–1475 (2012).
   PubMed Web of Science ®Google Scholar
• Seymour MT , BrownSR, MiddletonGet al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol.14(8), 749–759 (2013).
   PubMed Web of Science ®Google Scholar
• De Roock W , ClaesB, BernasconiDet al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol.11(8), 753–762 (2010).
   PubMed Web of Science ®Google Scholar
• Douillard J-Y , OlinerKS, SienaSet al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med.369(11), 1023–1034 (2013).
   PubMed Web of Science ®Google Scholar
• Tejpar S , LenzH-J, KohneC-Het al. Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: New results from the OPUS study. J. Clin. Oncol.32(Suppl. 3), Abstract LBA444 (2014).
   Google Scholar
• Ciardiello F , LenzH-J, KohneC-Het al. Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab. J. Clin. Oncol.32(Suppl.), Abstract 3506 (2014).
   PubMedGoogle Scholar
• Tournigand C , AndréT, AchilleEet al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol.22(2), 229–237 (2004).
   PubMed Web of Science ®Google Scholar
• Heinemann V , von WeikersthalLF, DeckerTet al. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). J. Clin. Oncol.31(Suppl.), Abstract LBA3506 (2013).
   Google Scholar
• Schwartzberg LS , RiveraF, KarthausMet al. PEAK: A randomized, multicenter Phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX5) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J. Clin. Oncol.32, 2240–2247 (2014).
   PubMed Web of Science ®Google Scholar
• Venook AP , NiedzwieckiD, LenzH-Jet al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (mCRC). J. Clin. Oncol.32(Suppl.), Abstract LBA3 (2014).
   Google Scholar
• Lenz H-J , NiedzwieckiD, InnocentiFet al. 501O: CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded RAS analyses untreated metastatic adenocarcinoma of the colon or rectum (mCRC). Presented at:ESMO 2014 Congress Madrid, Spain, 26–30 September 2014.
   Google Scholar
• Multi-line therapy in unresectable metastatic colorectal cancer (STRATEGIC-1)(2013). http://clinicaltrials.gov/show/NCT01910610
   Google Scholar
• Sequential treatment strategy for metastatic colorectal cancer (ITACa) (2013). http://clinicaltrials.gov/show/NCT01878422
   Google Scholar
• Medscape Education www.medscape.org/
   Google Scholar
• Medscape www.medscape.org/viewarticle/577606
   Google Scholar